Novartis restructures US field force

Published: 1-Dec-2010
Finance

Elimination of 1,400 General Medicines field force positions from January


Novartis Pharmaceuticals Corporation (NPC) is restructuring its General Medicines field force in the US to reflect changes in the product portfolio and align resources with strategic growth priorities. The company will reduce its General Medicines field force by approximately 1,400 positions from January 2011.

The product portfolio within the NPC General Medicines business is changing due to pending patent expirations and pipeline products. The restructuring is expected to result in a one-time cost of approximately US$85m.

‘NPC has a robust pipeline and the future growth potential for our organisation remains strong,’ said Andy Wyss, head of Novartis Pharma North America and President of Novartis Pharmaceuticals Corporation. ‘Proactively evolving our business model will enable us to focus our resources on key launch products and capture opportunities in both primary care and specialty medicines.’

See more

You may also like

Research & Development

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

Read more
The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production

Trending Articles

  1. Almac expands bioavailability capabilities to address a critical need in drug development Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
  2. Fidia Farmaceutici enters the UK market with the acquisition of Altacor Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group
  3. Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
  4. Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland
  5. Quintiles invests a further US$14m in China Will also expand lab testing capabilities with SCRC

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
Research & Development

Novartis bolsters kidney disease portfolio with Regulus Therapeutics acquisition

Through the acquisition, Novartis will gain access Regulus Therapeutics' oligonucleotide, farabursen, which is designed for the treatment of ADPKD
Manufacturing

Novartis to invest $23bn into US manufacturing and R&D capacity

The US investment will involve the construction of seven new manufacturing facilities, as well as a biomedical research innovation hub in San Diego
Finance

Novartis to acquire clinical-stage biopharma company, Anthos Therapeutics

Through the deal, Novartis will acquire Anthos' lead asset abelacimab, a fully human monoclonal anticoagulant designed to prevent stroke and systemic embolism in patients with atrial fibrillation
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Novartis completes acquisition of precision medicine developer Chinook

Novartis has announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics
Subscribe now